Posts by Steven A. Lubitz, MD, MPH
Primary Care Screening for Atrial Fibrillation in Older Adults Feasible But Inefficient
Massachusetts General Hospital researchers and colleagues found routine screening for atrial fibrillation (AF) using hand-held single-lead electrocardiography was accepted by 91% of older adults at primary care clinics, but screening did not significantly increase new AF diagnoses compared with usual care.
AI-based Analysis of ECGs Complements CHARGE-AF Score for Predicting AF
Steven A. Lubitz, MD, MPH, and Shaan Khurshid, MD, MPH, of the Cardiovascular Research Center, and colleagues developed a deep learning computer model that predicts five-year risk of atrial fibrillation using 12-lead ECG data, performing as well as the CHARGE-AF score and even better when combined with that score.
Stroke Subtype, Discharge Location Influence Use of Cardiac Rhythm Monitoring
Shaan Khurshid, MD, and Steven A. Lubitz, MD, MPH, of the Cardiovascular Research Center, and colleagues found that among 493 patients with acute ischemic stroke, only 37% received cardiac monitoring within six months as guidelines suggest.
Accelerometer Data Confirms: Increased Physical Activity Is Associated with Reduced Risk of Afib, Stroke
Using wrist-worn accelerometer data from the UK Biobank, Shaan Khurshid, MD, MPH, and Steven A. Lubitz, MD, MPH, of the Cardiovascular Research Center, and colleagues confirmed guideline-recommended levels of physical activity are associated with substantially lower risks of incident atrial fibrillation and stroke.
Non–Vitamin K Antagonist Oral Anticoagulants Are Safe for Selected Patients with Postoperative AF
Patrick T. Ellinor, MD, PhD, Steven A. Lubitz, MD, MPH, Thor M. Sundt, MD, and colleagues determined that after cardiac surgery, non–vitamin K antagonist oral anticoagulants are a safe alternative to warfarin for patients with nonvalvular atrial fibrillation who have acceptable bleeding risk.
Screening for AFib Using Wearable Activity Trackers and Telehealth
A Massachusetts General Hospital study is testing whether a novel software algorithm can be used to identify atrial fibrillation using wearable devices.
Multi-ancestry GWAS Identifies 141 New Loci Underlying Cardiac Conduction
An international collaboration provides important insights into the polygenic basis of cardiac conduction and the genetic relationship between PR interval duration and arrhythmias.
Atrial Fibrillation Risk Scoring at Time of Stroke May Identify People at Low Probability of Cardioembolism
Calculating the Electronic Health Record–Based AF score at the time of acute ischemic stroke may identify patients who do not need invasive rhythm monitoring.
Model Derived from Electronic Health Records System Predicts Risk of Atrial Fibrillation
Using data on more than 400,000 patients, Massachusetts General Hospital researchers developed and validated a novel prediction model for atrial fibrillation that also stratifies the risk of stroke.
Leveraging Social Media in Medicine
A group from the Massachusetts General Hospital Corrigan Minehan Heart Center discusses how they leverage social media as both practicing clinicians and active researchers.
Novel Genetic Signals for Heart Failure Identified
Researchers at Massachusetts General have found evidence of distinct genetic signals for heart failure—including some that operate independently of traditional risk factors for heart failure and associate with subclinical disease.
Frequency of Cardiac Rhythm Abnormalities in a Half Million Adults
Researchers at Massachusetts General Hospital recently published the results of their analysis of arrhythmias in the UK Biobank, a national cohort of over 500k community-based individuals recruited to assess risk factors for disorders affecting people from middle-age onward.
Using Polygenic Scores to Identify Risk of Afib and 4 Other Common Diseases
Polygenic risk scores developed at Massachusetts General Hospital are equivalent to or better than rare monogenic mutations in identifying a specific individual’s risk of certain common diseases, including coronary artery disease, atrial fibrillation and type 2 diabetes.
Lifetime Risk for Atrial Fibrillation Higher Than Expected
Lifetime risk for atrial fibrillation, while high, can be modified with health changes
Improved Identification of Patients at Risk for Atrial Fibrillation
Steve Lubitz, MD, MPH, discusses his team’s work focusing on understanding the mechanisms of atrial fibrillation through human genetics, and understanding how best to identify patients at risk for the arrhythmia.
#AHA17 Video: Scientific Sessions in Summary
Mass General physicians presented on the podium, moderated sessions or showcased posters over 50 times at the American Heart Association 2017 Scientific Sessions. Some of them answered the question: “What was the most interesting topic presented at this year’s Scientific Sessions?"
Dr. Lubitz graduated from the University of Michigan Medical School. He trained in internal medicine and cardiovascular disease at the Mount Sinai Hospital in New York, where he also served as a Chief Medical Resident. Dr. Lubitz earned a Master of Public Health degree from the Harvard University School of Public Health. He completed his clinical electrophysiology training at the Massachusetts General Hospital.
His clinical interests are focused on the diagnosis and treatment of patients with cardiac arrhythmias. He performs catheter ablations for supraventricular tachycardias (SVTs), and implantation and follow-up of pacemakers, cardiac resynchronization therapy (CRT) devices, and implantable cardioverter defibrillators (ICDs).
Dr. Lubitz has clinical and research interests in caring for patients with heritable arrhythmias, including early onset atrial fibrillation, Brugada syndrome, long QT syndrome, short QT syndrome, unexplained ventricular tachycardia and fibrillation, arrhythmogenic right ventricular cardiomyopathy, and catecholaminergic polymorphic ventricular tachycardia.
Dr. Lubitz is currently accepting new patients.